

## Prolia® (denosumab) - New indication

- On May 21, 2018, <u>Amgen announced</u> the <u>FDA approval</u> of <u>Prolia (denosumab)</u> for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk for fracture.
  - This includes men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of <u>prednisone</u> and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
- Prolia is also indicated for treatment:
  - Of postmenopausal women with osteoporosis at high risk for fracture
  - To increase bone mass in men with osteoporosis at high risk for fracture
  - To increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
  - To increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.
- The efficacy and safety of Prolia in the treatment of 795 patients with GIOP were assessed in the 12-month primary analysis of a 2-year study. Patients were randomized to <u>risedronate</u> 5 mg orally once daily or Prolia 60 mg subcutaneously (SC) once every 6 months for one year.
  - In the group receiving glucocorticoids for < 3 months at the beginning of the study, Prolia significantly increased lumbar spine bone mineral density (BMD) vs. risedronate (4.4% vs. 2.3%; difference = 2.2%; p < 0.001).</li>
  - In the group receiving glucocorticoids for ≥ 3 months at the beginning of the study, Prolia significantly increased lumbar spine BMD vs. risedronate (3.8% vs. 0.8%; difference = 2.9%; p < 0.001).</li>
- The most common adverse reactions (≥ 3% and more common than the active-control group) with Prolia use in GIOP were back pain, hypertension, bronchitis, and headache.
- The recommended dosage of Prolia for all indications is 60 mg administered as a single SC injection once every 6 months in the upper arm, upper thigh, or abdomen. Prolia should be administered by a healthcare professional.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.